AS03157 / Ascentage Pharma - LARVOL DELTA

Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs) (GlobeNewswire) - "AS03157 bound to cIAP1 and XIAP with high affinity and efficiently targeted cIAP1 for degradation, thereby generating potent antiproliferative activities (with IC50 values below 30 nM) in tested cancer cell lines. AS03157 demonstrated a favorable druggability profile. AS03157 showed promising in vivo activity in preclinical cancer models and displayed an acceptable safety profile."

Preclinical • Oncology

Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs) (AACR 2025) - "AS03157 showed promising in vitro and in vivo activity in preclinical cancer models, and these data provide a rationale for further clinical studies."

Breast Cancer • Oncology • Solid Tumor • BIRC3 • XIAP

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) - "Ascentage Pharma...announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Meeting (AACR)....The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist AS03157."

Preclinical • Acute Myelogenous Leukemia • Prostate Cancer • Small Cell Lung Cancer • T Acute Lymphoblastic Leukemia